Savara Competitors

Sesen Bio (NASDAQ:SESN) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Earnings and Valuation

This table compares Sesen Bio and Savara's top-line revenue, earnings per share and valuation.

Sesen Bio is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Sesen Bio and Savara, as provided by MarketBeat.

Sesen Bio presently has a consensus price target of $7.50, indicating a potential upside of 186.26%. Savara has a consensus price target of $4.6667, indicating a potential upside of 129.89%. Given Sesen Bio's higher probable upside, equities analysts plainly believe Sesen Bio is more favorable than Savara.

Volatility & Risk

Sesen Bio has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Savara has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Insider and Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 40.7% of Savara shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Comparatively, 4.8% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Sesen Bio and Savara's net margins, return on equity and return on assets.

Summary

Savara beats Sesen Bio on 6 of the 10 factors compared between the two stocks.

Savara (NASDAQ:SVRA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Savara and ANI Pharmaceuticals, as provided by MarketBeat.

Savara presently has a consensus price target of $4.6667, indicating a potential upside of 129.89%. ANI Pharmaceuticals has a consensus price target of $46.00, indicating a potential upside of 34.23%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than ANI Pharmaceuticals.

Insider & Institutional Ownership

40.7% of Savara shares are held by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are held by institutional investors. 4.8% of Savara shares are held by insiders. Comparatively, 24.8% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Savara and ANI Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

ANI Pharmaceuticals has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Savara and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Savara has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Summary

ANI Pharmaceuticals beats Savara on 7 of the 13 factors compared between the two stocks.

Savara (NASDAQ:SVRA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Earnings and Valuation

This table compares Savara and Puma Biotechnology's gross revenue, earnings per share (EPS) and valuation.

Puma Biotechnology has higher revenue and earnings than Savara. Puma Biotechnology is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

40.7% of Savara shares are owned by institutional investors. Comparatively, 87.9% of Puma Biotechnology shares are owned by institutional investors. 4.8% of Savara shares are owned by insiders. Comparatively, 21.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Savara and Puma Biotechnology's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for Savara and Puma Biotechnology, as reported by MarketBeat.com.

Savara currently has a consensus target price of $4.6667, suggesting a potential upside of 129.89%. Puma Biotechnology has a consensus target price of $12.50, suggesting a potential upside of 22.07%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Puma Biotechnology.

Risk & Volatility

Savara has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Summary

Savara beats Puma Biotechnology on 7 of the 13 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Evolus and Savara's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Evolus and Savara's revenue, earnings per share (EPS) and valuation.

Savara has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

21.7% of Evolus shares are held by institutional investors. Comparatively, 40.7% of Savara shares are held by institutional investors. 10.1% of Evolus shares are held by company insiders. Comparatively, 4.8% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Evolus and Savara, as provided by MarketBeat.

Evolus presently has a consensus price target of $13.8889, suggesting a potential upside of 45.59%. Savara has a consensus price target of $4.6667, suggesting a potential upside of 129.89%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Evolus.

Risk & Volatility

Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, Savara has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Summary

Savara beats Evolus on 8 of the 12 factors compared between the two stocks.

Savara (NASDAQ:SVRA) and MedAvail (NASDAQ:MDVL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Savara and MedAvail's net margins, return on equity and return on assets.

Volatility and Risk

Savara has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, MedAvail has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Savara and MedAvail, as reported by MarketBeat.

Savara currently has a consensus target price of $4.6667, suggesting a potential upside of 129.89%. MedAvail has a consensus target price of $20.00, suggesting a potential upside of 54.44%. Given Savara's higher probable upside, equities analysts plainly believe Savara is more favorable than MedAvail.

Earnings & Valuation

This table compares Savara and MedAvail's top-line revenue, earnings per share and valuation.

MedAvail has higher revenue and earnings than Savara. MedAvail is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

40.7% of Savara shares are owned by institutional investors. Comparatively, 40.2% of MedAvail shares are owned by institutional investors. 4.8% of Savara shares are owned by insiders. Comparatively, 45.3% of MedAvail shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Savara beats MedAvail on 8 of the 12 factors compared between the two stocks.

XOMA (NASDAQ:XOMA) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Valuation and Earnings

This table compares XOMA and Savara's top-line revenue, earnings per share (EPS) and valuation.

XOMA has higher revenue and earnings than Savara. XOMA is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

XOMA has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Savara has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

Institutional and Insider Ownership

57.2% of XOMA shares are held by institutional investors. Comparatively, 40.7% of Savara shares are held by institutional investors. 9.9% of XOMA shares are held by insiders. Comparatively, 4.8% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares XOMA and Savara's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations for XOMA and Savara, as provided by MarketBeat.com.

XOMA presently has a consensus price target of $46.00, indicating a potential upside of 23.29%. Savara has a consensus price target of $4.6667, indicating a potential upside of 129.89%. Given Savara's higher possible upside, analysts clearly believe Savara is more favorable than XOMA.

Summary

XOMA beats Savara on 7 of the 12 factors compared between the two stocks.